Why the study?
Does combination therapy with ACE inhibitors and calcium antagonists reduce hypertensive target organ disease in patients with hypertension compared to monotherapy?
Population
Patients with hypertension, hypertensive heart disease, renal disease, left ventricular hypertrophy, and…
Comparison
Combination therapy with Angiotensin-converting… vs Monotherapy
Design
Review
Authors
Loading...
Theoretical ACEI-CCB benefit for target organ damage should not change practice; leaves open need for RCTs on LVH and CHD outcomes.
Does combination therapy with ACE inhibitors and calcium antagonists reduce hypertensive target organ disease in patients with hypertension compared to monotherapy?
Combination therapy with ACE inhibitors and calcium antagonists shows theoretical promise for hypertensive target organ disease, but requires validation through prospective randomized trials.
Franz H. Messerli (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: